Evaluation of New Diagnostic Methods of Cardio-embolic Related (Atrial Fibrillation) Cerebral Infarction

Stroke Clinical Trial

— IRMA2  

Official title:

Evaluation of New Diagnostic Methods of Cardio-embolic Related (Atrial Fibrillation) Cerebral Infarction

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02948140
• Other study ID #: 2016/02
• Secondary ID: 2016-A00020-51
• Status: Terminated
• Phase: N/A
• Start date: June 13, 2016
• Est. completion date: December 2020

Study information

• Verified date: February 2021
• Source: Hopital Foch
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to estimate the contribution of abdominal imaging by magnetic resonance Imaging (MRI) and abdominal scanner in the detection of subdiaphragmatic infarction associated to the atrial fibrillation in the cerebral infarction.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 27
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient over 18

• Patient having a CHADS-VAsc Score = 2;

• Patient hospitalized for a secondary established ischemic accident in an atrial fibrillation not anticoagulated (INR<2 and/or receiving antiplatelet (aspirin, clopidogrel)) for less than 14 days;

• Patient affiliated to a national insurance scheme or beneficiary

• Patient having given a written consent

Exclusion Criteria:

• Patient presenting cognitive disorders incompatible with the planned examinations (MRI / SCANNER).

• Pacemaker or implantable defibrillator, or other contraindication in the MRI (metallic eye brightness, intra cerebral clip).

• Contraindication in injected scanner.

• Current pregnancy

Related Conditions & MeSH terms

• Atrial Fibrillation
• Cerebral Infarction
• Infarction
• Stroke

Intervention

Procedure:
• MRI

• Abdominal scanner

Locations

Country	Name	City	State
France	Hôpital Foch	Suresnes

Sponsors (1)

Lead Sponsor	Collaborator
Hopital Foch

Country where clinical trial is conducted

France, 

References & Publications (4)

Abboud H, Labreuche J, Gongora-Riverra F, Jaramillo A, Duyckaerts C, Steg PG, Hauw JJ, Amarenco P. Prevalence and determinants of subdiaphragmatic visceral infarction in patients with fatal stroke. Stroke. 2007 May;38(5):1442-6. Epub 2007 Mar 22. — View Citation

Flint AC, Tayal AH. The search for paroxysmal atrial fibrillation in cryptogenic stroke: leave no stone unturned. Neurology. 2013 Apr 23;80(17):1542-3. doi: 10.1212/WNL.0b013e31828f1938. Epub 2013 Mar 27. — View Citation

Slaoui T, Klein IF, Guidoux C, Cabrejo L, Meseguer E, Abboud H, Lavalllée PC, Mazighi M, Labreuche J, Amarenco P. Prevalence of subdiaphragmatic visceral infarction in cardioembolic stroke. Neurology. 2010 Mar 30;74(13):1030-2. doi: 10.1212/WNL.0b013e3181d76aaa. Epub 2010 Mar 3. — View Citation

White H, Boden-Albala B, Wang C, Elkind MS, Rundek T, Wright CB, Sacco RL. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation. 2005 Mar 15;111(10):1327-31. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with subdiaphragmatic infarctions detected by abdominal MRI		14 days
Secondary	Number of patients with subdiaphragmatic infarctions detected by abdominal scanner		14 days